1. Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group
- Author
-
Takeo Endo, Mitsuaki Sakai, Keiko Uchiumi, Takayuki Kaburagi, Masaharu Inagaki, Takeshi Nawa, Koichi Kamiyama, Yoshihiro Nishimura, Kenji Hayashihara, Toshihiko Fukuoka, Katsunori Kagohashi, Koji Kishi, Koichi Kurishima, Nobuyuki Hizawa, Takefumi Saito, Kinya Furukawa, Yoko Shinohara, Koji Unoura, Yukio Sato, Akihiro Nomura, Hiroichi Ishikawa, Hiroaki Satoh, Hideo Ichimura, Toshio Hashimoto, Takeshi Matsumura, and Hiroyuki Nakamura
- Subjects
Subset Analysis ,erlotinib ,Cancer Research ,medicine.medical_specialty ,Pathology ,Population ,Subgroup analysis ,elderly ,Internal medicine ,medicine ,Lung cancer ,education ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Cancer ,Articles ,medicine.disease ,Confidence interval ,population-based ,respiratory tract diseases ,non-small-cell lung cancer ,Oncology ,observational study ,Erlotinib ,business ,medicine.drug - Abstract
The incidence and mortality of lung cancer have increased worldwide over the last decades, with an observed increased incidence particularly among elderly populations. It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non-small-cell lung cancer (NSCLC). The aim of this retrospective subgroup analysis of data from a population-based observational study was to assess the efficacy and safety of erlotinib in an elderly (≥75 years, n=74) and a younger group of patients (
- Published
- 2013
- Full Text
- View/download PDF